Literature DB >> 35960373

Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.

Dmytro Oliinyk1, Teresa Augustin1, Josefine Rauch1, Viktoria Florentine Koehler2, Claus Belka1,3, Christine Spitzweg2,3, Lukas Käsmann4,5.   

Abstract

PURPOSE: Anaplastic thyroid carcinoma (ATC) is an orphan disease with a fatal outcome. Surgery to the primary tumor in metastatic ATC is controversial. Determination of specific surgical techniques may help facilitate local control and, hence, beneficial overall and disease-specific survival.
METHODS: Using individualized patient data derived from our systematic review of literature and our single center study (n = 123), conducting a Surveillance, Epidemiology, and End Results register (SEER)-based study (n = 617) we evaluated surgery, its combination with systemic and local therapies in metastatic ATC.
RESULTS: Pooled cohort study showed surgery (p < 0.001), RT ≥ 30 Gy (p < 0.001), ChT (p < 0.001) and multimodal treatment (p = 0.014) to result in improved OS univariately. In the multivariate analysis, surgery (1.997 [1.162-3.433], p = 0.012) and RT ≥ 30 Gy (1.877 [1.232-2.843], p = 0.012) were independent predictors for OS. In SEER-based study of patients undergoing any tumor-directed treatment (n = 445) total thyroidectomy (p = 0.031), administration of ChT (p = 0.007), RT (p < 0.001), combination of surgery and RT ± ChT (p < 0.001) and multimodal treatment (p < 0.001) correlated with an improved DSS univariately. On the multivariate analysis, debulking surgery was an independent predictor for a worse outcome (HR 0.535, 95%CI 0.332-0.862, p = 0.010), whereas RT administration correlated with a longer DSS (HR 2.316, 95%CI 1.362-3.939, p = 0.002). Among operated patients from SEER register total thyroidectomy (p = 0.031), ChT (p = 0.007), RT (p < 0.001), combination of surgery and RT ± ChT (p < 0.001) and multimodal treatment (p < 0.001) correlated with an improved DSS in the univariate analysis, whereas debulking surgery was inversely correlated with the DSS (p < 0.001). On the multivariate analysis, debulking surgery was an independent predictor for a worse DSS (HR 0.535, 95%CI 0.332-0.862, p = 0.010), whilst RT administration correlated with a longer DSS (HR 2.316, 95%CI 1.362-3.939, p = 0.002).
CONCLUSIONS: Surgery to the primary tumor with the aim of R0/R1 resection, but not debulking, is associated with a significant OS and DSS benefit even in systemically metastasized disease.
© 2022. The Author(s).

Entities:  

Keywords:  ATC; Anaplastic thyroid carcinoma; Surgery; Survival; Thyroidectomy

Year:  2022        PMID: 35960373     DOI: 10.1007/s00432-022-04223-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  63 in total

1.  Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma.

Authors:  Junko Akaishi; Kiminori Sugino; Wataru Kitagawa; Mitsuji Nagahama; Kaori Kameyama; Kazuo Shimizu; Kunihiko Ito; Koichi Ito
Journal:  Thyroid       Date:  2011-09-21       Impact factor: 6.568

2.  Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer.

Authors:  Teresa Augustin; Dmytro Oliinyk; Josefine Rauch; Viktoria Florentine Koehler; Christine Spitzweg; Claus Belka; Lukas KÄsmann
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

Review 3.  Evolution of chylous fistula management after neck dissection.

Authors:  Corrado C Campisi; Francesco Boccardo; Cesare Piazza; Corradino Campisi
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 2.064

4.  Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012.

Authors:  Seung-Kuk Baek; Myung-Chul Lee; J Hun Hah; Soon-Hyun Ahn; Young-Ik Son; Young-Soo Rho; Phil-Sang Chung; Yoon-Se Lee; Bon Seok Koo; Kwang-Yoon Jung; Byung-Joo Lee
Journal:  Head Neck       Date:  2016-08-18       Impact factor: 3.147

5.  Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012.

Authors:  Enrico Brignardello; Nicola Palestini; Francesco Felicetti; Anna Castiglione; Alessandro Piovesan; Marco Gallo; Milena Freddi; Umberto Ricardi; Guido Gasparri; Giovannino Ciccone; Emanuela Arvat; Giuseppe Boccuzzi
Journal:  Thyroid       Date:  2014-09-05       Impact factor: 6.568

6.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.

Authors:  B Busnardo; O Daniele; M R Pelizzo; R Mazzarotto; D Nacamulli; D Devido; C Mian; M E Girelli
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

7.  Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.

Authors:  K B Ain; M J Egorin; P A DeSimone
Journal:  Thyroid       Date:  2000-07       Impact factor: 6.568

8.  Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years.

Authors:  Enrico Brignardello; Marco Gallo; Ileana Baldi; Nicola Palestini; Alessandro Piovesan; Emidio Grossi; Giovannino Ciccone; Giuseppe Boccuzzi
Journal:  Eur J Endocrinol       Date:  2007-04       Impact factor: 6.664

9.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

10.  Protective Effects of Intraoperative Nerve Monitoring (IONM) for Recurrent Laryngeal Nerve Injury in Thyroidectomy: Meta-analysis.

Authors:  Binglong Bai; Wuzhen Chen
Journal:  Sci Rep       Date:  2018-05-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.